Cited by 3,066Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 65 of the 68 references it cites were found in a registry or an index.

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

Open access

Inzucchi, Silvio E., Bergenstal, Richard M., Buse, John B., Diamant, Michaela, Ferrannini, Ele, Nauck, Michael, Peters, Anne L., Tsapas, Apostolos, Wender, Richard, Matthews, David R.·2015·Diabetes Care

DOI 10.2337/dc14-2441

Open this paper in CoChat — free account

Abstract

In 2012, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a position statement on the management of hyperglycemia in patients with type 2 diabetes (1,2). This was needed because of an increasing array of antihyperglycemic drugs and growing uncertainty regarding their proper selection and sequence. Because of a paucity of comparative effectiveness research on long-term treatment outcomes with many of these medications, the 2012 publication was less prescriptive than prior consensus reports. We previously described the need to individualize both treatment targets and treatment strategies, with an emphasis on patient-centered care and shared decision making, and this continues to be our position, although there are now more head-to-head trials that show slight variance between agents with regard to glucose-lowering effects. Nevertheless, these differences are often small and would be unlikely to reflect any definite differential effect in an individual patient. The ADA and EASD have requested an update to the position statement incorporating new data from recent clinical trials. Between June and September of 2014, the Writing Group reconvened, including one face-to-face meeting, to discuss the changes. An entirely new statement was felt to be unnecessary. Instead, the group focused on those areas where revisions were suggested by a changing evidence base. This briefer article should therefore be read as an addendum to the previous full account (1,2). Glucose control remains a major focus in the management of patients with type 2 diabetes. However, this should always be in the context of a comprehensive cardiovascular risk factor reduction program, to include smoking cessation and the adoption of other healthy lifestyle habits, blood pressure control, lipid management with priority to statin medications, and, in some circumstances, antiplatelet therapy. Studies have conclusively determined that reducing hyperglycemia decreases the onset and progression of …

Integrity signals

Registry

Crossref · 10.2337/dc14-2441

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citation
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citation
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Self-citation
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Self-citation

Flagged first, then by citations

Show all 68 references

3 of the 68 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 1,014

Catalpol ameliorates hepatic insulin resistance in type 2 diabetes through acting on AMPK/NOX4/PI3K/AKT pathway
Yan, J., Wang, C., Jin, Y., Meng, Q., Liu, Q., Liu, Z., Liu, K., & Sun, H. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.026 · Cited by 251
Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine Society clinical practice guideline
Peters, A. L., Ahmann, A. J., Battelino, T., Evert, A., Hirsch, I. B., Murad, M. H., Winter, W. E., & Wolpert, H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2534 · Cited by 250
Self-citation
Management of diabetes in long-term care and skilled nursing facilities: a position statement of the American Diabetes Association
Munshi, M. N., Florez, H., Huang, E. S., Kalyani, R. R., Mupanomunda, M., Pandya, N., Swift, C. S., Taveira, T. H., & Haas, L. B. (2016) · Diabetes Care · doi:10.2337/dc15-2512 · Cited by 243
Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Levine, M. J. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666160613113556 · Cited by 241
Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: A European analysis of over 60 million glucose tests
Dunn, T. C., Xu, Y., Hayter, G., & Ajjan, R. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.12.015 · Cited by 239
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
Li, L., Li, S., Deng, K., Liu, J., Vandvik, P. O., Zhao, P., Zhang, L., Shen, J., Bała, M. M., Sohani, Z. N., et al. (2016) · BMJ · doi:10.1136/bmj.i610 · Cited by 238
Clinical inertia to insulin initiation and intensification in the UK: A focused literature review
Khunti, K., & Millar-Jones, D. (2016) · Primary care diabetes · doi:10.1016/j.pcd.2016.09.003 · Cited by 238
Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3070 · Cited by 239
7. Approaches to Glycemic Treatment
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s010 · Cited by 230
Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014
Carls, G., Huynh, J., Tuttle, E., Yee, J., & Edelman, S. V. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0280-5 · Cited by 228
Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY. 8th edition
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Vikulova, O. K., Galstyan, G. R., Кураева, Т. Л., Peterkova, V. A., Smirnova, O. M., Starostina, E. G., Surkova, E. V., et al. (2017) · Diabetes Mellitus · doi:10.14341/dm20171s8 · Cited by 224
Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Van Gaal, L., & Scheen, A. (2015) · Diabetes Care · doi:10.2337/dc14-1630 · Cited by 221
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial
Lingvay, I., Manghi, F. P., García-Hernández, P., Norwood, P., Lehmann, L., Tarp-Johansen, M. J., Buse, J. B., & for the DUAL V Investigators (2016) · JAMA · doi:10.1001/jama.2016.1252 · Cited by 220
Self-citation
5. Glycemic Targets
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s008 · Cited by 220
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
Sarafidis, P. A., Ferro, C. J., Morales, E., Ortíz, A., Małyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J. M., Fouque, D. P., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy407 · Cited by 216
Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study
Rajagopalan, H., Cherrington, A. D., Thompson, C. C., Kaplan, L. M., Rubino, F., Mingrone, G., Becerra, P., Rodriguez, P., Vignolo, P., Caplan, J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0383 · Cited by 216
Minimizing Hypoglycemia in Diabetes
International Hypoglycaemia Study Group (2015) · Diabetes Care · doi:10.2337/dc15-0279 · Cited by 218
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis From the EMPRISE Study
Patorno, E., Pawar, A., Franklin, J. M., Najafzadeh, M., Déruaz-Luyet, A., Brodovicz, K. G., Sambevski, S., Bessette, L. G., Santiago Ortiz, A. J., Kulldorff, M., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.039177 · Cited by 215
Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes ( CVD‐REAL Nordic ) when compared with dipeptidyl peptidase‐4 inhibitor therapy: Amultinational observational study
Persson, F., Nyström, T., Jørgensen, M. E., Carstensen, B., Gulseth, H. L., Thuresson, M., Fenici, P., Nathanson, D., Eriksson, J. W., Norhammar, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13077 · Cited by 212
Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial
Yabe, D., Nakamura, J., Kaneto, H., Deenadayalan, S., Navarria, A., Gislum, M., Inagaki, N., Arisaka, T., Asakura, T., Azuma, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30074-7 · Cited by 210
SGLT2 inhibitors and risk of cancer in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials
Tang, H., Dai, Q., Shi, W., Zhai, S., Song, Y., & Han, J. (2017) · Diabetologia · doi:10.1007/s00125-017-4370-8 · Cited by 206
Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management
Paschou, S. Α., Dede, A. D., Anagnostis, P. G., Vryonidou, A., Morganstein, D. L., & Goulis, D. G. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00042 · Cited by 206
Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysis
Khunti, K., Ceriello, A., Cos, X., & Block, C. E. M. D. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.12.004 · Cited by 206
6. Glycemic Targets
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s009 · Cited by 205
SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management
van Baar, M. J. B., van Ruiten, C. C., Muskiet, M. H. A., van Bloemendaal, L., IJzerman, R. G., & van Raalte, D. H. (2018) · Diabetes Care · doi:10.2337/dc18-0588 · Cited by 208
Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study
van Baar, A. C. G., Holleman, F., Crenier, L., Haidry, R., Magee, C., Hopkins, D., Rodriguez Grunert, L., Galvao Neto, M., Vignolo, P., Hayee, B., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318349 · Cited by 201
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Lupsa, B. C., & Inzucchi, S. E. (2018) · Diabetologia · doi:10.1007/s00125-018-4663-6 · Cited by 200
Self-citation
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Pοlyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. Α., Katsiki, N., UNDERWOOD, P. C., Park, K., Seufert, J., Kang, E. S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 196
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3a): the DERIVE Study
Fioretto, P., Del Prato, S., Buse, J. B., Goldenberg, R., Giorgino, F., Reyner, D., Langkilde, A. M., Sjöström, C. D., Sartipy, P., & On Behalf of the DERIVE Study Investigators (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13413 · Cited by 195
Self-citation
Exercise prescription in patients with different combinations of cardiovascular disease risk factors: a consensus statement from the EXPERT Working Group
Hansen, D., Niebauer, J., Cornelissen, V., Barna, O., Neunhäuserer, D., Stettler, C., Tonoli, C., Greco, E., Fagard, R., Coninx, K., et al. (2018) · Sports Medicine · doi:10.1007/s40279-018-0930-4 · Cited by 191
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Scheen, A. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0264-4 · Cited by 188
Diabetes and Cancer: Risk, Challenges, Management and Outcomes
Shahid, R. K., Ahmed, S., Le, D., & Yadav, S. (2021) · Cancers · doi:10.3390/cancers13225735 · Cited by 187
7. Approaches to Glycemic Treatment
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc15-s010 · Cited by 187
Japanese Clinical Practice Guideline for Diabetes 2016
Haneda, M., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Kondo, T., & Araki, E. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12810 · Cited by 184
Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes
Jones, A. G., McDonald, T. J., Shields, B. M., Hill, A. V., Hyde, C., Knight, B., & Hattersley, A. T. (2015) · Diabetes Care · doi:10.2337/dc15-0258 · Cited by 182
RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B. M., Ghosh, S. K., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 182
DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
Saini, K., Sharma, S., & Khan, Y. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1130625 · Cited by 185
EADSG Guidelines: Insulin Therapy in Diabetes
Silver, B., Ramaiya, K., Andrew, S. B., Fredrick, O., Bajaj, S., Kalra, S., Charlotte, B. M., Claudine, K., & Makhoba, A. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0384-6 · Cited by 179
Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
Sonesson, C., Johansson, P. A., JOHNSSON, E. K., & Gause‐Nilsson, I. A. M. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0356-y · Cited by 181
Diabetes mellitus and stroke: A clinical update
Tun, N. N., Arunagirinathan, G., Munshi, S. K., & Pappachan, J. M. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i6.235 · Cited by 177
Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence
Rodríguez-Gutiérrez, R., & Montori, V. M. (2016) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.002901 · Cited by 176
Effects of diabetes drugs on the skeleton
Meier, C., Schwartz, A. V., Egger, A., & Lecka‐Czernik, B. (2015) · Bone · doi:10.1016/j.bone.2015.04.026 · Cited by 174
Pharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 173
6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s006 · Cited by 172
Self-citation
Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function
Lazarus, B., Wu, A., Shin, J., Sang, Y., Alexander, G. C., Secora, A. M., Inker, L. A., Coresh, J., Chang, A. R., & Grams, M. E. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.0292 · Cited by 171
Association Between Preadmission Metformin Use and Outcomes in Intensive Care Unit Patients With Sepsis and Type 2 Diabetes: A Cohort Study
Yang, Q., Zheng, J., Chen, W., Chen, X., Wen, D., Chen, W., Xiong, X., & Zhang, Z. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.640785 · Cited by 171
Clinical Management of Intermittent Fasting in Patients with Diabetes Mellitus
Grajower, M. M., & Horne, B. D. (2019) · Nutrients · doi:10.3390/nu11040873 · Cited by 170
Dulce Digital: An mHealth SMS-Based Intervention Improves Glycemic Control in Hispanics With Type 2 Diabetes
Fortmann, A. L., Gallo, L. C., Garcia, M. I., Taleb, M., Euyoque, J. A., Clark, T., Skidmore, J., Ruiz, M., Dharkar-Surber, S., Schultz, J., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0230 · Cited by 169
Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta-analysis
McGovern, A., Tippu, Z., Hinton, W., Munro, N., Whyte, M., & de Lusignan, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13160 · Cited by 166
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Lorenz, M., Lawson, F., Owens, D., Raccah, D., Roy-Duval, C., Lehmann, A., Perfetti, R., & Blonde, L. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0490-6 · Cited by 166
Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes
Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09699-1 · Cited by 166
Management of Type 2 Diabetes in 2017
Reusch, J. E. B., & Manson, J. E. (2017) · JAMA · doi:10.1001/jama.2017.0241 · Cited by 163
Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights
Galicia-García, U., Jebari‐Benslaiman, S., Larrea, A., Uribe, K. B., Siddiqi, H. F., Ostolaza, H., Benito‐Vicente, A., & Martín, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134725 · Cited by 165
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)
F. Piepoli, M. (2017) · International Journal of Behavioral Medicine · doi:10.1007/s12529-016-9583-6 · Cited by 162
Gaps and barriers in the control of blood glucose in people with type 2 diabetes
Blonde, L., Aschner, P. J., Bailey, C. J., Ji, L., Leiter, L. A., Matthaei, S., & Management, O. B. O. T. G. P. F. E. D. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116679775 · Cited by 160
3. Foundations of Care and Comprehensive Medical Evaluation
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s006 · Cited by 159
Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control
Scheen, A. J., Esser, N., & Paquot, N. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.02.003 · Cited by 159
Therapeutic Concentrations of Metformin: A Systematic Review
Kajbaf, F., Broe, M. E. D., & Lalau, J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0323-x · Cited by 160
Chrono-nutrition for the prevention and treatment of obesity and type 2 diabetes: from mice to men
Hawley, J. A., Sassone‐Corsi, P., & Zierath, J. R. (2020) · Diabetologia · doi:10.1007/s00125-020-05238-w · Cited by 159
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
Jendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158
An International Position Statement on the Management of Frailty in Diabetes Mellitus: Summary of Recommendations 2017
Sinclair, A. J., Abdelhafiz, A. H., Dunning, T. L., Izquierdo, M., Rodríguez‐Mañas, L., Bourdel‐Marchasson, I., Morley, J. E., Munshi, M. N., Woo, J., & Vellas, B. J. (2018) · The Journal of Frailty & Aging · doi:10.14283/jfa.2017.39 · Cited by 158
Cardiac Autonomic Neuropathy in Diabetes: A Predictor of Cardiometabolic Events
Vinik, A. I., CASELLINI, C. M., Parson, H. K., Colberg, S. R., & Névoret, M.-L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00591 · Cited by 157
Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial
Rosenstock, J., Frías, J. P., Rodbard, H. W., Tofé, S., Sears, E., Huh, R., Fernández Landó, L., & Patel, H. (2023) · JAMA · doi:10.1001/jama.2023.20294 · Cited by 156
Sitagliptin: A Review in Type 2 Diabetes
Scott, L. J. (2017) · Drugs · doi:10.1007/s40265-016-0686-9 · Cited by 156
Empagliflozin: A Review in Type 2 Diabetes
Frampton, J. E. (2018) · Drugs · doi:10.1007/s40265-018-0937-z · Cited by 156
A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP ‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients
Abd El Aziz, M. S., Kahle, M., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12804 · Cited by 155
Self-citation
Exercise training for patients with type 2 diabetes and cardiovascular disease: What to pursue and how to do it. A Position Paper of the European Association of Preventive Cardiology (EAPC)
Kemps, H., Kränkel, N., Dörr, M., Moholdt, T. T., Wilhelm, M., Paneni, F., Serratosa, L., Solberg, E. E., Hansen, D., Halle, M., et al. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487318820420 · Cited by 154
Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes
Carls, G. S., Tuttle, E., Tan, R.-D., Huynh, J., Yee, J., Edelman, S. V., & Polonsky, W. H. (2017) · Diabetes Care · doi:10.2337/dc16-2725 · Cited by 153
Benefits and harms of intensive glycemic control in patients with type 2 diabetes
Rodriguez-Gutierrez, R., Gonzalez-Gonzalez, J. G., Zuñiga-Hernandez, J. A., & McCoy, R. G. (2019) · BMJ · doi:10.1136/bmj.l5887 · Cited by 152
Impact of health education on knowledge, attitude, practices and glycemic control in type 2 diabetes mellitus
Garg, R., Chawla, S. S., Kaur, S., Bharti, A., Kaur, M., Soin, D., Ghosh, A., & Pal, R. (2019) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_228_18 · Cited by 151
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M. T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0120 · Cited by 152
A Population-Based Study of the Bidirectional Association Between Obstructive Sleep Apnea and Type 2 Diabetes in Three Prospective U.S. Cohorts
Huang, T., Lin, B. M., Stampfer, M. J., Tworoger, S. S., Hu, F. B., & Redline, S. S. (2018) · Diabetes Care · doi:10.2337/dc18-0675 · Cited by 150
Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA ‐ T2D trial
Groop, P., Cooper, M. E., Perkovic, V., Hocher, B., Kanasaki, K., Haneda, M., Schernthaner, G., Sharma, K., Stanton, R. C., Toto, R. D., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13041 · Cited by 149
Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non‐alcoholic fatty liver disease: A randomized trial
Feng, W., Bi, Y., Li, P., Yin, T., Gao, C., Shen, S., Gao, L., Yang, D., & Zhu, D. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12888 · Cited by 149
Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study
Hung, S., Chang, Y., Liu, J., Kuo, K., Chen, Y., Hsu, C.-C., & Tarng, D. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00123-0 · Cited by 146
Impact of HbA1c Testing at Point of Care on Diabetes Management
Schnell, O., Crocker, J. B., & Weng, J. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816678263 · Cited by 147
Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus
Shi, Q., Liu, S., Fonseca, V. A., Thethi, T. K., & Shi, L. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024954 · Cited by 144
Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomized controlled clinical trial
Nauck, M., Rizzo, M., Johnson, A., Bosch-Traberg, H., Madsen, J., & Cariou, B. (2016) · Diabetes Care · doi:10.2337/dc15-2479 · Cited by 143
Self-citation
The diabetic foot in 2015: an overview
Markakis, K., Bowling, F. L., & Boulton, A. J. M. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2740 · Cited by 143
Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes
Rosenstock, J., Chuck, L. H. S., González-Ortı́z, M., Merton, K., Craig, J., Capuano, G. A., & Qiu, R. (2016) · Diabetes Care · doi:10.2337/dc15-1736 · Cited by 143
Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes
Elliott, L., Fidler, C., Ditchfield, A., & Stissing, T. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0157-z · Cited by 142
Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
Perkovic, V., Agarwal, R., Fioretto, P., Hemmelgarn, B. R., Levin, A., Thomas, M. C., Wanner, C., Kasiske, B. L., Wheeler, D. C., Groop, P., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.010 · Cited by 141
Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes
Dujić, T., Causevic, A., Bego, T., Malenica, M., Velija-Ašimi, Z., Pearson, E. R., & Semiz, S. (2015) · Diabetic Medicine · doi:10.1111/dme.13040 · Cited by 140
Association of metformin administration with gut microbiome dysbiosis in healthy volunteers
Elbere, I., Kalniņa, I., Silamiķelis, I., Konrāde, I., Zaharenko, L., Sekace, K., Radoviča-Spalviņa, I., Frīdmanis, D., Gudrā, D., Pīrāgs, V., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204317 · Cited by 139
Pathophysiology and Management of Type 2 Diabetes Mellitus Bone Fragility
Eller-Vainicher, C., Cairoli, E., Grassi, G., Grassi, F., Catalano, A., Merlotti, D., Falchetti, A., Gaudio, A., Chiodini, I., & Gennari, L. (2020) · Journal of Diabetes Research · doi:10.1155/2020/7608964 · Cited by 138
Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years
Liu, X., Zhang, N., Chen, R., Zhao, J., & Yu, P. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.07.011 · Cited by 137
The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial
Linjawi, S., Bode, B. W., Chaykin, L. B., Courrèges, J.-P., Handelsman, Y., Lehmann, L. M., Mishra, A., & Simpson, R. W. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0218-3 · Cited by 136
Utilization of a Cloud-Based Diabetes Management Program for Insulin Initiation and Titration Enables Collaborative Decision Making Between Healthcare Providers and Patients
Hsu, W. C., Lau, K. H. K., Huang, R., Ghiloni, S., Le, H., Gilroy, S., Abrahamson, M., & Moore, J. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0160 · Cited by 135
Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data
Dennis, J., Henley, W., Weedon, M. N., Lonergan, M. E., Rodgers, L. R., Jones, A. G., Hamilton, W. T., Sattar, N. A., Janmohamed, S. G., Holman, R. R., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0344 · Cited by 135
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial
Rosenstock, J., Guerci, B., Hanefeld, M., Gentile, S., Aronson, R., Tinahones, F. J., Roy-Duval, C., Souhami, E., Wardęcki, M., Ye, J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0014 · Cited by 134
Risk factors for diabetic foot complications in type 2 diabetes—A systematic review
Rossboth, S., Lechleitner, M., & Oberaigner, W. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.175 · Cited by 134
Regulation of biological processes by intrinsically chiral engineered materials
Ma, B., & Bianco, A. (2023) · Nature Reviews Materials · doi:10.1038/s41578-023-00561-1 · Cited by 133
Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
Kaku, K., Yamada, Y., Watada, H., Abiko, A., Nishida, T., Zacho, J., & Kiyosue, A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13218 · Cited by 132
Effect of canagliflozin on liver function tests in patients with type 2 diabetes
Leiter, L. A., Forst, T. M., Polidori, D., Balis, D. A., Xie, J., & Sha, S. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.10.003 · Cited by 132
RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017
Bajaj, S. (2018) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-018-0604-7 · Cited by 133
Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial
Søfteland, E. W., Meier, J. J., Vangen, B., Toorawa, R., Maldonado‐Lutomirsky, M., & Broedl, U. C. (2016) · Diabetes Care · doi:10.2337/dc16-1347 · Cited by 130
The safety of gliptins : updated data in 2018
Scheen, A. J. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1444027 · Cited by 130
Pharmacologic Therapy for Type 2 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes
Chamberlain, J. J., Herman, W. H., Leal, S., Rhinehart, A. S., Shubrook, J. H., SKOLNIK, N., & Kalyani, R. R. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2937 · Cited by 129
One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer
Luginbuhl, K. M., Schaal, J. L., Umstead, B. R., Mastria, E. M., Li, X., Banskota, S., Arnold, S. E., Feinglos, M. N., D’Alessio, D. A., & Chilkoti, A. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0078 · Cited by 129
User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists
Shaefer, C. F., Kushner, P., & Aguilar, R. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1090295 · Cited by 128

Authors: Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R.
Affiliations: Yale New Haven Hospital (US)
Park Nicollet Health Services (US)
University of North Carolina at Chapel Hill (US)
Diabetes Center/Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands
University of Pisa (IT)
Diabeteszentrum Bad Lauterberg (DE)
University of Southern California (US)
Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece
American Cancer Society (US)
Churchill Hospital (GB)
Corresponding author: Inzucchi, Silvio E.
ORCID: Inzucchi, Silvio E.
Bergenstal, Richard M.
Buse, John B.
Ferrannini, Ele
Nauck, Michael
Peters, Anne L.
Wender, Richard
Matthews, David R.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2014-12-13
Volume: 38
Issue: 1
Pages: 140-149
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dc14-2441
OpenAlex: W2160088494
Cited by: 3,066
References: 68
Citations by year: 2026: 52 · 2025: 84 · 2024: 96 · 2023: 135 · 2022: 138 · 2021: 142 · 2020: 202 · 2019: 313 · 2018: 482 · 2017: 545 · 2016: 540 · 2015: 325 · 2014: 7
FWCI: 380.40
Type: journal article
Language: en
Open access: green
pure.amsterdamumc.nl
Licence: other-oa
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion, other-oa)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: Bristol-Myers Squibb
Eli Lilly and Company
AstraZeneca
GlaxoSmithKline
Sanofi
Massachusetts General Hospital
Yale University
Kaiser Permanente
F. Hoffmann-La Roche
Case Western Reserve University
School of Medicine, Case Western Reserve University
Intarcia Therapeutics
National Institute for Health and Care Research
University of Sydney
Universiteit van Amsterdam
University of Toronto
Novo Nordisk
Uniwersytet Łódzki
European Association for the Study of Diabetes
Université de Nantes
Servier
Lilly Deutschland
University of Ioannina
School of Medicine, University of Kansas
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: type 2 diabetes, hyperglycemia management, antidiabetic drugs, patient-centered care, shared decision-making, glucose-lowering agents, cardiovascular risk reduction, smoking cessation, blood pressure control, lipid control, statins, antiplatelet therapy, lifestyle modification
MeSH terms: Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Combinations, Humans, Hyperglycemia, Metformin, United States, Disease Management, Glycemic Index, Thiazolidinediones, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks